Merck Dives Further Into Cytokine Research With Synthekine Deal

by Vandana Singh, Benzinga Editor

November 1, 2021 12:42 PM | 1 min read |

Synthekine Inc has entered a worldwide research collaboration and license agreement with Merck & Co Inc MRK.
The big pharma has agreed to co-develop two new cytokine-based therapies by leveraging Synthekine’s proprietary surrogate cytokine agonist platform.
Although the deal doesn’t appear to offer much upfront, the partners didn’t disclose Merck’s initial payment, and it comes with $525 million in milestones per target.
Merck will provide research funding to Synthekine for programs under the collaboration.
The new deal will also focus first on autoimmunity.
Price Action: MRK shares are down 0.12% at $87.94 during the market session on the last check Monday.

Posted In: Biotech News Health Care Contracts General Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.